<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Karyopharm's revenue and expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/14/2025 06:22pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Karyopharm's revenue was $30.54 million in Q4 2024, while their R&amp;D expenses were $33.3 million, and their SG&amp;A expenses were not provided. The company reported a net loss of $30.78 million for the quarter.


|code|Ticker|Name|Date|R&amp;D Expenses|Total Revenue|Net Income|market_code|
|---|---|---|---|---|---|---|---|
|KPTI|KPTI.O|Karyopharm|2024 Q1|3.5425E7|3.3126E7|-3.7362E7|185|
|KPTI|KPTI.O|Karyopharm|2024 Q2|3.8371E7|4.2786E7|2.3792E7|185|
|KPTI|KPTI.O|Karyopharm|2024 Q3|3.6134E7|3.8783E7|-3.2072E7|185|
|KPTI|KPTI.O|Karyopharm|2024 Q4|3.3302E7|3.0542E7|-3.078E7|185|

</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay){return {layout:"default",data:[{noData:c,currentQuestion:g,textDescription:W,comeFrom:"AInvestShareLink",events:[],answerSource:p}],fetch:{},error:q,state:{sharePreviewModule:{loadJgySuccess:d,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:h,agent_id:a,output_media_info:[],task_id:a,language:a,source:p,cache_builder:a,reply_action:"Answer",execute_mode:I,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Karyopharm's revenue and expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Karyopharm's revenue and expenses trend in Q4 2024?\",\"user_id\":\"dp24322243\",\"user_name\":\"\",\"trace_id\":\"246a18e2-32bc-4444-aed3-eb12ffb9233b\",\"session_id\":\"246a18e2-32bc-4444-aed3-eb12ffb9233b\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:j,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Total Revenue[20241231]|R&D Expenses[20241231]|Net Income[20241231]|Report End Date|\n|---|---|---|---|---|---|---|---|\n|KPTI|Karyopharm|$4.29|7.52%|$30.54 million|$33.3 million|-$30.78 million|20241231|\n",query_data:{number:h,title:J,query_type:j,condition:a,model_sql:X,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d}}}],answer_chain_name:Y,agent_mode:Z,native_answer:a,come_from:a,text_answer:W,trace_id:i,cost:18626,event_names:a,question:g,fallback_type:_,input_type:$,fall_back_reason:{fall_back_type:_,risk_detail:{matched_words:[]}},session_id:i,first_return_cost:3614,cache_type:a,question_id:i,transfer_question:g,signal_type:"ON_COMPLETE",start_time:aa,remote_svc:p,slots:[],answer_type:I,user_id:z,skill_name:K},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:i,session_id:i,user_id:z,question:g,source:p,raw_question:g,version:"3.4.1",action_name:K,nlu:{entity:[{type:L,value:r,market:k}]},deep_research:c,deep_thinking:c,agent_mode:Z},extra:{}},{answer_path:A,section:{id:B,info_texts:["Thinking"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:A,section:{id:B,info_texts:["Querying Stock: KPTI Revenue(Q4 2024), R&D Expenses(Q4 2024), SG&A Expenses(Q4 2024), Net Income(Q4 2024)"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:J,thought:"The user seeks to analyze Karyopharm's Q4 2024 revenue and expense trends. I should focus on its Q4 2024 revenue, R&D expenses, SG&A expenses, and net income data. I will use FinQuery for the data mentioned above."}},{answer_path:e,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:A,section:{id:B,info_texts:["Generating Answer"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:e,section:{id:m,info_texts:[],show_type:D,voice_txt:"K",text_answer:ab,rich_text:ab,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:2000,info_texts:[],show_type:D,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:J,query_type:j,trace_data:a,index:h,model_sql:X,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:m,info_texts:[],show_type:D,voice_txt:".\n\n",text_answer:ac,rich_text:ac,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:t,market_id:k,name:n,domain:L},pos:d,section_id:m,txt:n,jump_type:ad},{stock_info:{code:ae,market_id:"169",name:"Sweetgreen",domain:L},pos:107,section_id:m,txt:ae,jump_type:ad}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:m,info_texts:[],show_type:af,choice:[],result_page:{components:[{uuid:"1fa93fe1714dedcc",config:{score:116,show_type:ag,scoreRuleNames:"value_unit;data_size;",showDataZoom:b,show_type_id:131,title:"分组柱状图",render:{x:u,y:[E,F,G]},title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:ah,h2:a},show_type:M}},data:{chunks_info:"[]",code_count:h,columns:[{index_name:N,key:N,label:"hq_code",source:O,type:f},{domain:v,feKey:P,index_name:P,key:P,label:N,origin_index:"stock code",source:O,type:f,unit:a},{domain:v,feKey:Q,index_name:Q,key:Q,label:"name",origin_index:"stock name",source:O,type:f,unit:a},{feKey:u,index_name:u,key:u,label:"date",origin_index:u,type:"DATE"},{domain:v,feKey:E,index_name:E,key:E,label:a,source:a,timestamp:a,type:R,unit:S},{domain:v,feKey:F,index_name:F,key:F,label:a,source:a,timestamp:a,type:R,unit:S},{domain:v,feKey:G,index_name:G,key:G,label:a,source:a,timestamp:a,type:R,unit:S},{index_name:ai,key:ai,type:f}],condition:"[{\"sonSize\":6,\"opName\":\"and\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"indexProperties\":[\"EQUAL KPTI.O\"],\"indexPropertiesMap\":{\"EQUAL\":\"KPTI.O\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":4,\"opName\":\"or\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@R\\u0026D Expenses\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Net Income\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Total Revenue\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"domain\":\"abs_国际美股领域\",\"relatedSize\":0}]",dataSize:4,datas:[{"Net Income":-37362000,code:t,"R&D Expenses":35425000,"Total Revenue":33126000,Ticker:r,market_code:k,Date:"2024 Q1",Name:n},{"Net Income":23792000,code:t,"R&D Expenses":38371000,"Total Revenue":42786000,Ticker:r,market_code:k,Date:"2024 Q2",Name:n},{"Net Income":-32072000,code:t,"R&D Expenses":36134000,"Total Revenue":38783000,Ticker:r,market_code:k,Date:"2024 Q3",Name:n},{"Net Income":-30780000,code:t,"R&D Expenses":33302000,"Total Revenue":30542000,Ticker:r,market_code:k,Date:"2024 Q4",Name:n}],meta:{extra:{}},row_count:h,status_code:d,status_msg:"ok"},category:"generic",chart_type:"groupedBar",show_type:ag,title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:ah,h2:a},show_type:M},support_refresh:b,data_config:{query:a,query_type:j,data_ext_params:{}}}],global:{query_type:j},page:{language:a,layout:{layout_data:"[{\"children\":[],\"showType\":\"bar3\",\"uuid\":\"1fa93fe1714dedcc\"}]"},render_for:T},data_config:{query:a,query_type:j,data_ext_params:{}}},tag_info_list:[],is_last:c,uuid:"118a1922-3fc4-4962-8f4b-6060c7bad4dd"},logs:[],extra:{}},{answer_path:e,section:{id:m,info_texts:[],show_type:D,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:A,section:{id:B,info_texts:["Completed"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:af,choice:[{display_text:w,query_text:w,trace_info:{item_id:"59a17761428066a1dc204a09942d538c",item_type:o,item_name:w,rec_info:aj}},{display_text:x,query_text:x,trace_info:{item_id:"186f02481e10130c3f4a18bb75339123",item_type:o,item_name:x,rec_info:ak}},{display_text:y,query_text:y,trace_info:{item_id:"bea071675bc4837a0da49aa479230cfb",item_type:o,item_name:y,rec_info:al}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:M,data:{h1:a,h2:a},config:{display:c,txt_style:d,type:"1",display2:c,url:a}},request_config:[{source_type:am,related_name:an}],puuid:U,tag:a,category:"custom",uuid:ao}],global:{urp_static_data:[{name:an,value:{status_code:d,columns:[{type:f,index_name:ap,key:ap},{type:f,index_name:aq,key:aq},{type:f,index_name:ar,key:ar},{type:f,index_name:as,key:as},{type:f,index_name:at,key:at}],datas:[{send_text:w,item_type:o,rec_info:aj,display_text:w,rec_reason:a},{send_text:x,item_type:o,rec_info:ak,display_text:x,rec_reason:a},{send_text:y,item_type:o,rec_info:al,display_text:y,rec_reason:a}],dataSize:am,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:au,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:H,"min-height":"100%",position:av,height:H},isMaterial:c,id:au,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:d,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:V,componentUuid:ao,script:[{name:aw,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:V,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:V},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:H,position:av,height:H},isMaterial:b,_id:19,id:aw,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:T,voice_txt:a,tracking_info:{},uuid:U},order:{is_auto:c,render_for:T,chart_type:"command",puuid:U}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:K,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:I,answer_chain_name:Y},is_deep_research:c,deep_thinking:c,create_time:1744626162682},is_last:b}],questionItem:{data:{qStr:g,encodeFlag:c,imageData:q,docsData:[],quoteData:q},tplType:"question"},events:ax,agentId:a,param:{entity_info:{},add_info:{ori_question:g},event_list:ax,client_ip:a,question:g,user_id:z,user_name:a,trace_id:i,session_id:i,source:p,input_type:$}}],userId:z,userName:a,startTime:aa,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:q,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:d,traceTableData:q,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-karyopharms-revenue-and-expenses-trend-in-q4-2024-3a4da1\u002F",config:{_app:{basePath:ay,assetsPath:ay,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,0,"other\u002FopenAnswer","STR","How did Karyopharm's revenue and expenses trend in Q4 2024?",1,"246a18e2-32bc-4444-aed3-eb12ffb9233b","intusstock","185","signal",2001,"Karyopharm","llm_generated","ths_ainvest_lite_web",null,"KPTI.O",999,"KPTI","Date","abs_国际美股领域","What was Karyopharm's net income for Q4 2024?","What were Karyopharm's revenue figures for Q4 2024?","How did Karyopharm's operating expenses change in Q4 2024 compared to previous quarters?","dp24322243","progress\u002Fsearching_for",1000,"searching_for","rich_text","R&D Expenses","Total Revenue","Net Income","auto","agent","KPTI Revenue(Q4 2024), R&D Expenses(Q4 2024), SG&A Expenses(Q4 2024), Net Income(Q4 2024)","inspect stocks","stock","title1","code","fixed_index","Ticker","Name","DOUBLE","USD","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Karyopharm's revenue was $30.54 million in Q4 2024, while their R&D expenses were $33.3 million, and their SG&A expenses were not provided. The company reported a net loss of $30.78 million for the quarter.\n\n\n|code|Ticker|Name|Date|R&D Expenses|Total Revenue|Net Income|market_code|\n|---|---|---|---|---|---|---|---|\n|KPTI|KPTI.O|Karyopharm|2024 Q1|3.5425E7|3.3126E7|-3.7362E7|185|\n|KPTI|KPTI.O|Karyopharm|2024 Q2|3.8371E7|4.2786E7|2.3792E7|185|\n|KPTI|KPTI.O|Karyopharm|2024 Q3|3.6134E7|3.8783E7|-3.2072E7|185|\n|KPTI|KPTI.O|Karyopharm|2024 Q4|3.3302E7|3.0542E7|-3.078E7|185|\n\n","select   stock_code,   total_revenue,   r_d_expenses,   net_income from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'KPTI.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1744626144056,"Karyopharm's revenue was $30.54 million in Q4 2024, while their R&D expenses were $33.3 million, and their SG&A expenses were not provided. The company reported a net loss of $30.78 million for the quarter[^1]",".\n\n\n``` visual\n{\"uuid\":\"118a1922-3fc4-4962-8f4b-6060c7bad4dd\"}\n```","pos_fenshi","SG","result_page","bar3","KPTI R&D Expenses, Total Revenue...","market_code","2+679_496_21_554+0+0+246a18e2-32bc-4444-aed3-eb12ffb9233b+59a17761428066a1dc204a09942d538c+llm_generated+aimeTagAnalysis+0+0.11030234396457672+1","2+679_496_21_554+0+0+246a18e2-32bc-4444-aed3-eb12ffb9233b+186f02481e10130c3f4a18bb75339123+llm_generated+aimeTagAnalysis+0+0.09267620742321014+2","2+679_496_21_554+0+0+246a18e2-32bc-4444-aed3-eb12ffb9233b+bea071675bc4837a0da49aa479230cfb+llm_generated+aimeTagAnalysis+0+0.05414572358131409+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>